Side effects
If you experience any of the following symptoms, stop taking tolterodine and contact your doctor right away. You should also seek emergency medical attention if necessary. Dry mouth, heartburn, headache, constipation, diarrhea, dry eyes, dry skin, joint pain, excessive fatigue, difficulty emptying the bladder painfully, weight gain, anxiety, swelling of the face, throat, tongue, lips, and eyes, as well as difficulty swallowing or breathing. Inform your doctor if any of these symptoms persist or are particularly bothersome: dry mouth, heartburn, headache, constipation, diarrhea, dry eyes, dry skin, joint pain, excessive fatigue, painful urination, weight gain, anxiety, swelling of the face, throat, tongue, lips, and eyes, and difficulty swallowing or breathing. Some side effects can be very serious. There may be negative effects from tolterodine.
Interactions
For more details, consult your physician or pharmacist. Tell your doctor right away if you take any of the following medications in addition to tolterodine: clarithromycin, cyclosporin, erythromycin, itraconazole, ketoconazole, miconazole, vinblastine. If you take tolterodine with other medicines, the effects of either could be increased, decreased, or altered. Inform your doctor of all the drugs you are taking or intend to take, including vitamins, herbal supplements, prescription and non-prescription medications.
Contraindications
Ask your pharmacist for a list of the ingredients. tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. If you use any of the following medications, make sure to mention them: amiodarone (Nexterone, Pacerone); antihistamines; atazanavir (Reyataz, in Evotaz); clarithromycin; cyclosporine (Gengraf, Neoral, Sandimmune); donepezil (Aricept, in Namzaric); erythromycin (E.E.S., Ery-Tab, others); galant Inform your doctor and pharmacist if you have any allergies before taking tolterodine, including those to other medicines, tolterodine, fesoterodine fumarate (Toviaz), or any of the ingredients in tolterodine tablets or extended-release capsules. Before you know how this medication affects you, do not operate machinery or drive a car. Tolterodine may cause you to feel drowsy or woozy, or it may cause blurred vision or other vision problems. If you become pregnant while taking tolterodine, call your doctor. Tolsura; drugs for irritable bowel syndrome, motion sickness, or Parkinson's disease; ketoconazole; procainamide; quinidine (in Nuedexta); ritonavir (Norvir, in Kaletra, Technivie, Viekira); rivastigmine (Exelon); saquinavir (Invirase); sotalol (Betapace, Sorine, Sotylize); and Tell your doctor if you have or have ever had glaucoma (increased pressure in the eyes that may cause vision loss), urinary retention (inability to empty your bladder completely or at all), or gastric retention (slow emptying of your stomach). Your doctor may advise against taking tolterodine.
Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel). erythromycin and clarithromycin), antifungal agents (e.g. Concomitant medication with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effect and side-effects. ketoconazole and itraconazole) and antiproteases is not recommended due to increased serum concentrations of tolterodine in poor CYP2D6 metabolisers with (subsequent) risk of overdosage (see section 4.4).
Absorption Distribution Metabolism Extensively hepatic, primarily via CYP2D6 to 5-hydroxymethyltolterodine (active) and 3A4 usually (minor pathway). Excretion Urine (77%); feces (17%); primarily as metabolites (<1% unchanged drug) of which the active 5-hydroxymethyl metabolite accounts for 5% to 14% (<1% in poor metabolizers); as unchanged drug (<1%; <2.5% in poor metabolizers) Time to Peak Immediate release tablet: 1-2 hours; Extended release capsule: 2-6 hours Half-Life Elimination Immediate release tablet: Extensive metabolizers: ~2 hours; Poor metabolizers: ~10 hours Extended release capsule: Extensive metabolizers: ~7 hours; Poor metabolizers: ~18 hours Protein Binding In patients with a genetic deficiency of CYP2D6, metabolism via 3A4 predominates.
ketoconazole and itraconazole) and antiproteases is not recommended due to increased serum concentrations of tolterodine in poor CYP2D6 metabolisers with (subsequent) risk of overdosage (see section 4.4). Concomitant medication with other drugs that possess antimuscarinic properties may result in more pronounced therapeutic effect and side-effects. Concomitant treatment with fluoxetine (a potent CYP2D6 inhibitor) does not result in a clinically significant interaction since tolterodine and its CYP2D6-dependent metabolite, 5-hydroxymethyl tolterodine are equipotent. Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel). Conversely, the therapeutic effect of tolterodine may be reduced by concomitant administration of muscarinic cholinergic receptor agonists.
Conversely, the therapeutic effect of tolterodine may be reduced by concomitant administration of muscarinic cholinergic receptor agonists. Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel). A clinical study has indicated that tolterodine is not a metabolic inhibitor of CYP2D6, 2C19, 2C9, 3A4 or 1A2.
Conversely, the therapeutic effect of tolterodine may be reduced by concomitant administration of muscarinic cholinergic receptor agonists. Drug interaction studies have shown no interactions with warfarin or combined oral contraceptives (ethinyl estradiol/levonorgestrel). A clinical study has indicated that tolterodine is not a metabolic inhibitor of CYP2D6, 2C19, 2C9, 3A4 or 1A2. erythromycin and clarithromycin), antifungal agents (e.g. Concomitant systemic medication with potent CYP3A4 inhibitors such as macrolide antibiotics (e.g.
The drug, Terol is present in the tablet form. Terol LA- 4 mg consists of active ingredient Tolterodine tartrate. Buy Terol LA- 4 mg online to treat your overactive bladder syndrome.
• After three months of treatment with mirabegron 50mg daily, the number of urinations was reduced by an average of 1.8 per day, compared with a reduction of 1.2 per day for placebo. The co-primary efficacy endpoints were reduction from baseline to final visit in mean number of micturitions and mean number of incontinence episodes per day. • Mirabegron produced similar reductions to tolterodine in the mean number of micturitions and episodes of incontinence per day from the first measured time point (one month) until study end. The incidence and severity of adverse events were logged over 12 months.